Follow
György  Bodoky
György Bodoky
oncologist at St.László kórház
Verified email at hungarnet.hu
Title
Cited by
Cited by
Year
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer
E Van Cutsem, CH Köhne, E Hitre, J Zaluski, CR Chang Chien, ...
New England Journal of Medicine 360 (14), 1408-1417, 2009
48212009
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
J Bruix, S Qin, P Merle, A Granito, YH Huang, G Bodoky, M Pracht, ...
The Lancet 389 (10064), 56-66, 2017
34332017
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
E Van Cutsem, A Cervantes, R Adam, A Sobrero, JH Van Krieken, ...
Annals of Oncology 27 (8), 1386-1422, 2016
33912016
Panitumumab–FOLFOX4 treatment and RAS mutations in colorectal cancer
JY Douillard, KS Oliner, S Siena, J Tabernero, R Burkes, M Barugel, ...
New England Journal of Medicine 369 (11), 1023-1034, 2013
25632013
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a …
H Wilke, K Muro, E Van Cutsem, SC Oh, G Bodoky, Y Shimada, ...
The lancet oncology 15 (11), 1224-1235, 2014
24432014
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with …
JY Douillard, S Siena, J Cassidy, J Tabernero, R Burkes, M Barugel, ...
Journal of clinical oncology 28 (31), 4697-4705, 2010
22012010
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
AV Balar, MD Galsky, JE Rosenberg, T Powles, DP Petrylak, J Bellmunt, ...
The Lancet 389 (10064), 67-76, 2017
20532017
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making
HJ Schmoll, E Van Cutsem, A Stein, V Valentini, B Glimelius, ...
Annals of oncology 23 (10), 2479-2516, 2012
18242012
Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial
AD Roth, S Tejpar, M Delorenzi, P Yan, R Fiocca, D Klingbiel, D Dietrich, ...
J Clin Oncol 28 (3), 466-474, 2010
14202010
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open …
A Wang-Gillam, CP Li, G Bodoky, A Dean, YS Shan, G Jameson, ...
The Lancet 387 (10018), 545-557, 2016
11462016
ESPEN guidelines on enteral nutrition: non-surgical oncology
J Arends, G Bodoky, F Bozzetti, K Fearon, M Muscaritoli, G Selga, ...
Clinical nutrition 25 (2), 245-259, 2006
10222006
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with …
J Tabernero, T Yoshino, AL Cohn, R Obermannova, G Bodoky, ...
The Lancet Oncology 16 (5), 499-508, 2015
9812015
Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial
F Lordick, YK Kang, HC Chung, P Salman, SC Oh, G Bodoky, G Kurteva, ...
The lancet oncology 14 (6), 490-499, 2013
9442013
Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer …
R Herrmann, G Bodoky, T Ruhstaller, B Glimelius, E Bajetta, J Schuller, ...
Journal of Clinical Oncology 25 (16), 2212-2217, 2007
7452007
Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial
JA Ajani, W Rodriguez, G Bodoky, V Moiseyenko, M Lichinitser, ...
Journal of clinical oncology 28 (9), 1547-1553, 2010
7122010
Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer
JY Douillard, S Siena, J Cassidy, J Tabernero, R Burkes, M Barugel, ...
Annals of Oncology 25 (7), 1346-1355, 2014
6342014
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial
A de Gramont, E Van Cutsem, HJ Schmoll, J Tabernero, S Clarke, ...
The lancet oncology 13 (12), 1225-1233, 2012
6342012
Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3
E Van Cutsem, R Labianca, G Bodoky, C Barone, E Aranda, B Nordlinger, ...
J Clin Oncol 27 (19), 3117-3125, 2009
5982009
Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an …
PC Thuss-Patience, MA Shah, A Ohtsu, E Van Cutsem, JA Ajani, H Castro, ...
The lancet oncology 18 (5), 640-653, 2017
4902017
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
T Powles, T Csőszi, M Özgüroğlu, N Matsubara, L Géczi, SYS Cheng, ...
The Lancet Oncology 22 (7), 931-945, 2021
3922021
The system can't perform the operation now. Try again later.
Articles 1–20